Predictors of NIV Treatment in Patients with COPD Exacerbation Complicated by Respiratory Acidaemia.


Journal

COPD
ISSN: 1541-2563
Titre abrégé: COPD
Pays: England
ID NLM: 101211769

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 1 10 2020
medline: 10 11 2021
entrez: 30 9 2020
Statut: ppublish

Résumé

Non-invasive ventilation (NIV) treatment decisions are poorly understood for patients with COPD exacerbation complicated by acute hypercapnic respiratory failure and respiratory acidaemia (ECOPD-RA). We identified 420 NIV-eligible patients from the DECAF study cohorts admitted with an ECOPD-RA. Using bivariate and multivariate analyses, we examined which indices were associated with clinicians' decisions to start NIV, including whether the presence of pneumonia was a deterrent. Admitting hospital, admission from institutional care, partial pressure of oxygen, cerebrovascular disease, pH, systolic blood pressure and white cell count were all associated with the provision of NIV. Of these indices, only pH was also a predictor of inpatient death. Those not treated with NIV included those with milder acidaemia and higher (and sometimes excessive) oxygen levels, and a frailer population with higher Extended Medical Research Council Dyspnoea scores, presumably deemed not suitable for NIV. Pneumonia was not associated with NIV treatment; 34 of 111 (30.6%) NIV-untreated patients had pneumonia, whilst 107 of 309 (34.6%) NIV-treated patients had pneumonia (

Identifiants

pubmed: 32993401
doi: 10.1080/15412555.2020.1823358
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

492-498

Auteurs

Carlos Echevarria (C)

Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.
Translational and Clinical Research Institute, Medical School, Newcastle University, Newcastle Upon Tyne, UK.

John Steer (J)

Translational and Clinical Research Institute, Medical School, Newcastle University, Newcastle Upon Tyne, UK.
North Tyneside General Hospital, Newcastle Upon Tyne, UK.

Tom Hartley (T)

North Tyneside General Hospital, Newcastle Upon Tyne, UK.

Nicholas Lane (N)

North Tyneside General Hospital, Newcastle Upon Tyne, UK.

Stephen C Bourke (SC)

Translational and Clinical Research Institute, Medical School, Newcastle University, Newcastle Upon Tyne, UK.
North Tyneside General Hospital, Newcastle Upon Tyne, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH